TC Transcontinental has acquired two companies from the Canva Group - Mirazed Inc. and Intergraphics Decal Limited - to strengthen its in-store marketing capabilities in Quebec and Western Canada, adding over 200 skilled employees and advanced production facilities.

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.67% to 32,412.36 while the NASDAQ rose 0.39% to 12,079.66. The S&P also rose, gaining, 0.59% to 4,047.22. Also check this: Bitcoin Drops Further To This Level, Here Are Other Crypto Movers That Should Be On Your Radar Leading and Lagging Sectors Real estate shares rose 2.9% on Thursday. Meanwhile, top gainers in the sector included Equinix, Inc. (NASDAQ: EQIX), up 8% and Transcontinental Realty Investors, Inc. (NYSE: TCI) up 6%. In trading on Thursday, communication services shares fell 1.5%. Top Headline The US economy shrank an annualized 0.9% on quarter during the second quarter, compared to a 1.6% decline in the first quarter. Equities Trading UP JAKKS Pacific, Inc. (NASDAQ: JAKK) shares shot up 35% to $23.00 after the company reported better-than-expected Q2 results. Shares of ToughBuilt Industries, Inc. (NASDAQ: TBLT) got a boost, shooting 32% to $6.05 after the company entered into an agreement with Ace Hardware USA to sell 35 products across 5,500 stores. SKYX ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces Procurement Of 1.4M Additional Doses Of COVID-19 Pill By U.S. Merck & Co., Inc. (NYSE: MRK) said its pending acquisition of Acceleron Pharma, Inc. (NASDAQ: XLRN) has been cleared by the competition authorities in Germany and Austria. The cash tender offer Merck has commenced to purchase all outstanding shares of common stock of Acceleron, for $180 per share in cash will expire at 5 p.m. on Nov. 18. The acquisition is expected to close in the fourth quarter. Separately, Merck and Ridgeback Biotherapeutics announced the U.S. government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted emergency use authorization or approval by the U.S. Food and Drug Administration, for approximately $1 billion. With these exercised options, the U.S. has now committed to purchase a total of approximately 3.1 million courses of molnupiravir, for approximately $2.2 billion, between authorization and early 2022. The U.S. government also has the ability to purchase more than 2 million additional courses through further options that remain in the contract. Merck shares were up 1.29% at $83.75 in premarket trading. Alkermes Receives Partial Termination Notices For Licensing Agreement With Janssen Over Technology Uses In Latter's Antipsychotic Drugs Alkermes plc (NASDAQ: ALKS) announced that it received notices of partial termination of two license agreements with Johnson & Johnson (NYSE: JNJ)'s Janssen unit. The terminations impact know-how royalties related to sales of long-acting paliperidone products, such as Invega Sustenna and Invega Trinza in the U.S. Even as Janssen maintained that it does not utilize Alkermes' "NanoCrystal" technology licensed under the agreements, Alkermes said it strongly disagrees with Janssen's position. The latter also said it will explore all options at its disposal to enforce its contractual rights and address any unauthorized use of its intellectual property. Alkermes shares were receding 7.94% to $27 in premarket trading. Related Link: The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Amgen Migraine Treatment Found Superior To Standard-Of-Care In Phase 4 Study Amgen, Inc. (NASDAQ: AMGN) announced new data from the a head-to-head Phase 4 study of Aimovig, a CGRP inhibitor, against topiramate for adult patients with episodic and chronic migraine. Topiramate is one of the most commonly prescribed medications in migraine prevention. The study conducted by Novartis AG (NYSE: NVS) showed that patients in the ...

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89%. Merck & Co., Inc. (MRK: NYSE), which also has a competing medication in the pipeline, shed close to 10% on Friday. Stocks also reacted to the earnings, which came in thick and fast during the week. Five stocks belonging to the biotech and diagnostics spaces, debuted on Wall Street during the week. Here are the key upcoming catalysts that biotech investors are on in the unfolding week: Health Care Conferences: American College of Rheumatology, or ACR, Convergence 2021: Nov. 3-9 (virtual) BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology: Nov. 8 (virtual event) Credit Suisse 30th Annual Virtual Healthcare Conference: Nov. 8-11 (virtual conference) 14th Clinical Trial On Alzheimer's Disease, or CTAD, 2021: Nov. 9-12 (in Boston) 6th Respiratory Syncytial Virus Network, or RESVINET, Conference: Nov. 10-12 (virtual meeting) Society For Immunotherapy of Cancer: Nov. 10-14 (hybrid event, to be held in Washington, D.C. and to be available virtually) Connective Tissue Oncology Society, or CTOS, 2021 Annual Meeting: Nov. 10-13 (virtual meeting) American Academy of Ophthalmology, or AAO, 2021 Meeting: Nov. 12-13 (in New Orleans) American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2021: Nov. 12-15 (virtual meeting) Clinical Readouts/Presentations Liver Meeting Presentations Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA): Phase 1b data for EDP-514 in viremic, chronic hepatitis B infected patients Vir Biotechnology, Inc. (NASDAQ: VIR): Preliminary results from a Phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody, for hepatitis B infection (Friday, at 8 a.m.) Vaccitech plc (NASDAQ: VACC): Interim results of HBV001, a Phase 1 study evaluating therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection; Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with Bristol-Myers Squibb Company's (NYSE: BMY) low-dose Opdivo in virally-suppressed patients with CHB under nucleos(t)ide analogues Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA): results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346, which Dicerna is developing in collaboration with Roche Holding AG (OTC: RHHBY) for the treatment of chronic hepatitis B virus infection; interim Phase 1 data from Belcesiran in Alpha 1-antitrypsin deficiency-associated liver disease Lipocine Inc. (NASDAQ: LPCN): safety And tolerability Of LPCN 1144 treatment In biopsy confirmed NASH subjects from the Phase 2 LiFT study Arbutus Biopharma Corporation (NASDAQ: ABUS): data on the effects of its ...

Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI) jumped 23.4% to close at $10.50 on Tuesday after the company announced it was awarded an IDIQ contract under the US Army's $1.25 billion conformal wearable battery program. The company will receive no more than $168 million over a 3 year base period. Obalon Therapeutics, Inc. (NASDAQ: OBLN) surged 22% to settle at $2.88. Moxian, Inc. (NASDAQ: MOXC) gained 21% to close at $13.53. Aemetis, Inc. (NASDAQ: AMTX) jumped 20.9% to close at $12.30. Park City Group, Inc. (NASDAQ: PCYG) climbed 20.7% to close at $6.17 on Tuesday after reporting Q3 results. Agenus Inc. (NASDAQ: AGEN) shares gained 20.6% to close at $3.93 on Tuesday. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 and a second undisclosed target. Agrify Corporation (NASDAQ: AGFY) gained 20.5% to settle at $9.18. Agrify posted its first-quarter earnings results Monday, reporting revenue of $7 million, compared to $4.4 million and $1 million in the previous quarter and the same quarter of 2020, respectively. Virios Therapeutics, Inc. (NASDAQ: VIRI) rose 20.4% to close at $5.67 as traders circulated an article from Zacks titled 'Initiating Coverage Of Virios Therapeutics; Attacking The Root Cause Of Chronic Disease.' Inotiv, Inc. (NASDAQ: NOTV) jumped 20.2% to close at $25.25 after dropping 9% on Monday. Lordstown Motors Corp. (NASDAQ: RIDE) gained 20.1% to settle at $10.09. Lordstown Motors shares gained around 15% on Monday after the company set the dates for its "Lordstown Week" event. Orbital Energy Group, Inc. (NASDAQ: OEG) surged 19.5% to close at $3.55, rebounding after the stock dipped on Monday following worse-than-expected Q1 EPS and sales results. China HGS Real Estate Inc. (NASDAQ: HGSH) surged 18.4% to settle at $2.19 after the company reported a sharp rise in 1H sales. Aterian, Inc. (NASDAQ: ATER) jumped 18.2% to close at $16.20. Aterian recently reported a Q1 loss of $3.15 per share. NN, Inc. (NASDAQ: NNBR) jumped 18% to settle at $9.37. NN recently added Rajeev Gautam as a Director. Vor Biopharma Inc. (NASDAQ: VOR) gained 17.8% ...Full story available on Benzinga.com